The estimated Net Worth of John Mark O'mahony is at least $13.9 Tausend dollars as of 26 January 2024. John mahony owns over 5,000 units of Leap Therapeutics Inc stock worth over $13,850 and over the last 5 years John sold LPTX stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John mahony LPTX stock SEC Form 4 insiders trading
John has made over 1 trades of the Leap Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently John exercised 5,000 units of LPTX stock worth $13,850 on 26 January 2024.
The largest trade John's ever made was exercising 5,000 units of Leap Therapeutics Inc stock on 26 January 2024 worth over $13,850. On average, John trades about 500 units every 0 days since 2020. As of 26 January 2024 John still owns at least 5,000 units of Leap Therapeutics Inc stock.
You can see the complete history of John mahony stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's John mahony's mailing address?
John's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE, MA, 02141.
Insiders trading at Leap Therapeutics Inc
Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli und Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.
What does Leap Therapeutics Inc do?
leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.
What does Leap Therapeutics Inc's logo look like?
Complete history of John mahony stock trades at Leap Therapeutics Inc
Leap Therapeutics Inc executives and stock owners
Leap Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Douglas Onsi,
President, Chief Executive Officer, Director -
Augustine Lawlor,
Chief Operating Officer -
Christopher Mirabelli,
Chairman of the Board -
Cynthia Sirard,
Chief Medical Officer -
Mark O'Mahony,
Chief Manufacturing Officer -
Nissim Mashiach,
Independent Director -
Joseph Loscalzo,
Independent Director -
William Li,
Independent Director -
Thomas Dietz,
Lead Independent Director -
James Cavanaugh,
Independent Director -
Monica Bertagnolli,
Independent Director -
John W Littlechild,
Director -
Ventures Ix, L.P.Healthcare...,
-
Harold R Werner,
10% owner -
Lilly & Co Eli,
10% owner -
Patricia A. Martin,
Director -
Christian M Richard,
Director -
Richard Schilsky,
Director -
Advisors Llcperceptive Life...,
-
Ventures Viii, L.P.Health C...,
-
Jason Baum,
Chief Scientific Officer -
Christine Granfield,
VP, Head of Reg Affairs/Qual -
Ltd. Bei Gene,,
10% owner